Platelet [3H]imipramine binding in generalized anxiety disorder, panic disorder, and agoraphobia with panic attacks.
The density of platelet [3H]imipramine binding sites is reported to be decreased in unipolar depression and, hence, is a putative biological marker. There is considerable evidence for a phenomenological and biological relationship of panic disorder with affective disorder. We studied platelet [3H]imipramine binding site density in unmedicated subjects with generalized anxiety disorder (GAD; n = 55), panic disorder (PD) with and without agoraphobia (n = 52), and normal controls (n = 26) in order to determine whether or not patients with panic disorder differed from controls in this biological assay. We found no differences in binding site density (Bmax) or affinity (Kd) among the PD, PD with agoraphobia, GAD, and control groups. Nor did we find a relationship between Bmax or Kd and the severity of depressive symptoms or the presence of a family history of affective disorder. In view of two conflicting prior studies, the use of [3H]imipramine binding in panic disorder remains problematic.
D000328:Adult; D000379:Agoraphobia / Q000097:blood; D001008:Anxiety Disorders / Q000097:blood*; D001792:Blood Platelets / Q000378:metabolism*; D005260:Female; D006801:Humans; D007099:Imipramine / Q000097:blood*; D007700:Kinetics; D008297:Male; D008875:Middle Aged; D010200:Panic / Q000502:physiology; D010698:Phobic Disorders / Q000097:blood*
D007099:Imipramine